Therapeutic angiogenesis in cardiovascular disease
暂无分享,去创建一个
[1] J. Hartikainen,et al. Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT) , 2003, Circulation.
[2] Shahin Rafii,et al. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration , 2003, Nature Medicine.
[3] P. Ratcliffe,et al. Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.
[4] M. Simons,et al. Translational physiology: porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis. , 2003, Journal of applied physiology.
[5] M. Simons,et al. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. , 2003, Trends in cardiovascular medicine.
[6] M. Voskuil,et al. Modulation of collateral artery growth in a porcine hindlimb ligation model using MCP-1. , 2003, American Journal of Physiology. Heart and Circulatory Physiology.
[7] Philippe Leboulch,et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2 , 2003, Nature Medicine.
[8] Brian H Annex,et al. The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .
[9] R. Hajjar,et al. Decreased Efficiency of Adenovirus-Mediated Gene Transfer in Aging Cardiomyocytes , 2003, Circulation.
[10] W. Schaper,et al. Arteriogenesis: the development and growth of collateral arteries. , 2003, Microcirculation.
[11] Bernd Westphal,et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration , 2003, The Lancet.
[12] Hung-Fat Tse,et al. Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation , 2003, The Lancet.
[13] W. Schaper,et al. Blood monocyte concentration is critical for enhancement of collateral artery growth. , 2002, American journal of physiology. Heart and circulatory physiology.
[14] Moon-Kyoung Bae,et al. Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation , 2002, Cell.
[15] J. Ware,et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. , 2002, The Journal of thoracic and cardiovascular surgery.
[16] R. Lederman,et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial , 2002, The Lancet.
[17] D. Warltier,et al. Angiostatin Inhibits Coronary Angiogenesis During Impaired Production of Nitric Oxide , 2002, Circulation.
[18] Jian Li,et al. Increased responsiveness of hypoxic endothelial cells to FGF2 is mediated by HIF-1alpha-dependent regulation of enzymes involved in synthesis of heparan sulfate FGF2-binding sites. , 2002, Journal of cell science.
[19] R. Hendel,et al. Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia , 2002, Circulation.
[20] P. Carmeliet,et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro‐angiogenic therapy , 2002, The EMBO journal.
[21] E. Scott,et al. Bone marrow cells adopt the phenotype of other cells by spontaneous cell fusion , 2002, Nature.
[22] Qi-Long Ying,et al. Changing potency by spontaneous fusion , 2002, Nature.
[23] C. Grines,et al. Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris , 2002, Circulation.
[24] Robert J Lederman,et al. Incomplete retention after direct myocardial injection , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[25] T. Henry,et al. Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.
[26] M. Goldberg,et al. Gene expression profiles in human cardiac cells subjected to hypoxia or expressing a hybrid form of HIF-1α , 2002 .
[27] D. Latchman,et al. In vivo myocardial gene transfer: optimization and evaluation of intracoronary gene delivery in vivo , 2001, Gene Therapy.
[28] M. Moses,et al. HIF-1alpha-mediated up-regulation of vascular endothelial growth factor, independent of basic fibroblast growth factor, is important in the switch to the angiogenic phenotype during early tumorigenesis. , 2001, Cancer research.
[29] M. Simons,et al. Therapeutic coronary angiogenesis: a fronte praecipitium a tergo lupi? , 2001, American journal of physiology. Heart and circulatory physiology.
[30] N. Weissman,et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. , 2001, Journal of the American College of Cardiology.
[31] Andrew D. Miller,et al. In vivo myocardial gene transfer: Optimization, evaluation and direct comparison of gene transfer vectors , 2001, Basic Research in Cardiology.
[32] S. Homma,et al. Neovascularization of ischemic myocardium by human bone-marrow–derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function , 2001, Nature Medicine.
[33] F. Sellke,et al. Therapeutic angiogenesis in cardiology using protein formulations. , 2001, Cardiovascular research.
[34] R. B. Johnson,et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. , 2001, Journal of the American College of Cardiology.
[35] G. Franklin,et al. The Sequential Activation and Repression of the Human PDGF-B Gene During Chronic Hypoxia Reveals Antagonistic Roles for the Depletion of Oxygen and Glucose , 2001, Growth factors.
[36] R O Bonow,et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary. , 2000, Circulation.
[37] T. Ogihara,et al. Novel molecular therapeutic approach to cardiovascular disease based on hepatocyte growth factor. , 2000, Journal of atherosclerosis and thrombosis.
[38] M. Goldberg,et al. Angiogenesis Is Induced in a Rabbit Model of Hindlimb Ischemia by Naked DNA Encoding an HIF-1&agr;/VP16 Hybrid Transcription Factor , 2000, Circulation.
[39] Keelan,et al. The Coronary Venous System: An Alternate Portal to the Myocardium for Diagnostic and Therapeutic Procedures in Invasive Cardiology. , 2000, Current interventional cardiology reports.
[40] E. Levin,et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing , 1999, Nature Medicine.
[41] S. Mudaliar,et al. Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise. , 1999, American journal of physiology. Heart and circulatory physiology.
[42] J. Pearlman,et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a phase I randomized, double-blind, placebo-controlled trial. , 1999, Circulation.
[43] K. Seibert,et al. COX‐2 Inhibitors: A New Class of Antiangiogenic Agents , 1999, Annals of the New York Academy of Sciences.
[44] P Lavie,et al. Interindividual heterogeneity in the hypoxic regulation of VEGF: significance for the development of the coronary artery collateral circulation. , 1999, Circulation.
[45] F. Sellke,et al. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[46] D. Zipes,et al. Efficient in vivo catheter‐based pericardial gene transfer mediated by adenoviral vectors , 1999, Clinical cardiology.
[47] J. Spertus,et al. Comparison of three quality of life instruments in stable angina pectoris: Seattle Angina Questionnaire, Short Form Health Survey (SF-36), and Quality of Life Index-Cardiac Version III. , 1998, Journal of Clinical Epidemiology.
[48] F. Sellke,et al. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. , 1997, The American journal of physiology.
[49] W. Schaper,et al. Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion. , 1997, Circulation research.
[50] J. Ware,et al. Angiogenesis in ischemic heart disease , 1997, Nature Medicine.
[51] W. Schaper,et al. Molecular mechanisms of coronary collateral vessel growth. , 1996, Circulation research.
[52] J. Pearlman,et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. , 1996, The American journal of physiology.
[53] S. Signoretti,et al. Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. , 1996, Gene therapy.
[54] M. Voskuil,et al. Effects of local MCP-1 protein therapy on the development of the collateral circulation and atherosclerosis in Watanabe hyperlipidemic rabbits. , 2003, Cardiovascular research.
[55] A. Luttun,et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1 , 2002, Nature Medicine.
[56] J. Michel,et al. Increasing endothelial cell permeability improves the efficiency of myocyte adenoviral vector infection , 2001, The journal of gene medicine.
[57] P. Carmeliet,et al. PR39, a peptide regulator of angiogenesis , 2000, Nature Medicine.
[58] W. Schaper,et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. , 1998, The Journal of clinical investigation.